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Background Although cervical cancer is a preventable disease, the clinical and economic 
burdens of cervical cancer are still substantial issues in Indonesia. 
 
Methods We developed a population-based Markov Model, consisting of three health states 
(susceptible, cervical cancer and death) to assess future costs, health effects and the cost-
utility of cervical cancer prevention strategies in Indonesia. We followed a cohort of 100,000 
women from 12 to 100 years old and compared Visual Inspection with Acetic acid (VIA) 
screening alone with the addition of Human Papillomavirus (HPV) vaccination on top of the 
screening to no intervention. 
 
Results The implementation of VIA screening alone and in combination with HPV vaccination 
would reduce the cervical cancer incidence by 7.9% and 58,5%, corresponding to 25 and 98 
deaths avoided within the cohort of 100,000, respectively. We also estimated that HPV 
vaccination combined with VIA screening apparently yielded a lower incremental cost-
effectiveness ratio (ICER) at I$1,863/QALYs, compared to VIA screening alone 
(I$3,126/QALYs). Both strategies could, however, be definitely labeled as very cost-effective 
interventions, based on a threshold suggested by the World Health Organization. The ICER 
was sensitive to the discount rate, cervical cancer treatment costs and quality of life as part 
of the QALY.  
 
Conclusion The addition of HPV vaccination on top of VIA screening could be a cost-effective 
strategy in Indonesia even if relatively conservative assumptions are applied. This 
population-based model can be considered as an essential tool to inform decision makers on 
designing optimal strategies for cervical cancer prevention in Indonesia. 
 




Cervical cancer is the second most common cancer among women in Indonesia. The age-
standardized cervical cancer incidence and mortality rates per 100,000 women in 2012 were 
17.3 and 8.1, respectively (1). The long onset of cervical cancer development (2,3) enables 
the application of cervical screening to prevent and control cervical cancer. Despite the poor 
sensitivity of Visual Inspection with Acetic acid (VIA) screening (4), it is the most commonly 
recommended screening strategy for countries with limited resources (5). Well-organized 
VIA screening programs definitely decrease the burden of cervical cancer at relatively low 
costs (6,7). The Ministry of Health, Republic of Indonesia launched a cervical cancer control 
program in 2007 and started a campaign recommending VIA screening for all susceptible 




program, such as limited screening coverage, poor quality of services and subsequent poor 
cryotherapy performance (11). 
 
In addition to the screening program, the introduction of prophylactic HPV vaccination of 
girls against two high-risk HPV types (16 and 18) (12), which together are responsible for the 
large majority of cervical cancer development, offers primary prevention of cervical cancer 
(5,7). There are two available HPV vaccines in the market and their efficacies against HPV 
infections and Cervical Intraepithelial Neoplasm (CIN) have been demonstrated in numerous 
clinical trials (13–17). Next to the efficacy and safety of vaccines, the available national 
budget for vaccination and affordability present other main considerations for a country to 
implement a vaccination program. Although the cost-effectiveness of HPV vaccination has 
been proven in many studies (18–22), those findings not necessarily apply to Indonesia as 
many differences in clinical profiles, patient- and population characteristics and health-care 
systems among countries exist. 
 
Although a new health insurance system has been implemented from 2014 onwards in 
Indonesia, pharmacoeconomic studies have not yet been incorporated as criteria into the 
decision-making process. However, cost-utility studies on cervical cancer prevention can 
provide valuable information for the decision maker to design the most cost-effective 
strategy to reduce the clinical and economic burdens of HPV-related disease among 
Indonesian women, within the limited budget. The main purpose of this study is to model 
the costs, clinical benefits and cost-utility of both VIA screening alone and HPV vaccination in 
addition to VIA screening in Indonesia. To interpret the findings from this study, we applied 




We developed a population-based Markov model for Indonesia by using Microsoft® Excel. 
The model (as shown in Figure 1) consists of 3 health states (susceptible, cervical cancer and 
death), which represents the major stages throughout the natural history of infection and 
cervical cancer. In our model, “susceptible for cancer” refers to healthy women, but also to 
infected women with CIN but (yet) without cancer. This simplification was made to 
accommodate with the limited data availability in Indonesia; notably, more complicated 
models would lack the data to populate them. Additionally, in annual cycles, women may 
move through “cervical cancer” and “death” states. We hypothesized a cohort of 100,000 
12-year-old girls before sexual debut as the initial situation in the model (25), followed until 
100 years old. To estimate the natural history of cervical cancer, we applied 2012 WHO’s life 
table on age-dependent incidence and mortality rate specific for cervical cancer in Indonesia 
(26,27). The transition from “cervical cancer” to “death” resulted from death caused by 
cancer as well as by other diseases. We performed our analysis from the payer’s perspective, 
based on national tariffs that were recently launched by the Ministry of Health for all 
treatments in primary care and hospitals (28). 
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Figure 1. Markov model for the development of cervical cancer 
We compared three strategies in the base-case: (i) without any intervention (reference); (ii) 
with VIA screening; (iii) with VIA screening and HPV vaccination. Both unvaccinated and 
vaccinated groups were followed in the model with differing risks until the potential 
screening process. Cryotherapy treatment was assumed to be performed as a part of 
positive individuals when pre-cancer stages would be detected. Specific proportions of 
deaths, cancer cases and recovered patients followed from VIA screening efficacies related 
to the prevention of cervical cancer (29). In addition, we assumed that 15.8% of new cervical 
cancer patients will have a recurrence and undergo an additional/recurrence treatment (30). 
The model parameters and baseline values specifically adopted for Indonesia can be seen in 
Table 1. 
 
Screening and Vaccination 
Despite the extensive communication and the introduction of the national VIA screening 
program in 2007, the performance of this program remains sub-optimal (11). In our study, 
we assumed implementation of the screening for 30- until 60-year-old women within an 
annual interval of 3 years if the previous test was negative, according to the 
recommendation (8,9). We assumed that 63,6% of eligible (“susceptible” in the model) 
women would perform VIA screening every 3 years (29). We applied a detection rate of VIA 
screening of 69.4% (31) and an adherence rate to cryotherapy of 83.1% (11), based on 
previous studies in Indonesia. Furthermore, a study by Sankaranarayanan et al. showed that 
the incidence and mortality hazard ratios for screened women were 0.75 and 0.65, 












Table 1. Parameters used in the economic model: base-case values and distributions applied 
in the probabilistic sensitivity analysis 
 
Parameters Value Distribution References 
Estimated proportion of HPV 
16/18 in cervical cancer 
75.4% Triangular (71.0%; 75.4%; 100.0%) (30–32) 
Cervical cancer recurrence 15.8% Triangular (3.4%; 15.8%; 23.2%) (33) 
HPV Vaccination 
Vaccine coverage 76.6% Triangular (76.1%; 76.6%; 77.1%) (34,35)* 
Vaccine price (I$) 14.76 - (36)**  
Vaccine efficacy – percent 
reduction in HPV 16/18 persistent 
infection 
95.0% Triangular (90.4%; 95.0%; 98.1%) (13,37) 
Screening 
Age range 30-60 - (8,9,29) 
Coverage (3 yearly) 63,6% Triangular (50,1%; 63,6%; 70,5%) (29) 
Efficacy to cervical cancer 
incidence 
75.0% Triangular (59.0%; 75.0%; 95.0%) (29) 
Efficacy to cervical cancer 
mortality 
65.0% Triangular (47.0%; 65.0%; 89.0%) (29) 
Detection rate (confirmed) 9.9% Triangular (2.5%; 9.9%; 12.8%) (29) 
Cryotherapy coverage 83.1% Triangular (13.0%; 83.1%; 100.0%) (11) 
Costs 
Initial treatment of cervical cancer 
(I$) 
4,140 Triangular (2,335; 4,140; 5,825) (28,38–40)***  
Recurrence treatment of cervical 
cancer (I$) 
3,169 Triangular (1,842, 3,169; 4,415) (28,38–40)***  
Cryotherapy (I$) 26.29 - (41) 
Screening (I$) 4.38 - (41) 
Discount rate 3% - (24) 
Utility 
Susceptible 1 - Assumed 
Cervical cancer 0.68 Triangular (0.48; 0.63; 0.84) (42) 
Death 0 - Assumed 
Discount rate 3% - (24) 
*estimated from school enrollment rate and vaccination coverage for measles, diphtheria, and tetanus for 
7-12 years old girls in Indonesia 
**includes 3 doses of vaccine, revolving fund, freight, insurance and wastage cost 
***estimated from the national tariffs and weighted by the pattern of cervical cancer treatment in 
Indonesia 
 
The vaccine efficacy against HPV type 16 and 18 infections was estimated from available 
clinical trials (13,32,33), without taking cross-protection against HPV types other than 16 and 
18 into account in the base-case. The proportion of high-risk HPV (hrHPV) was estimated 
from three different studies in Indonesia (34–36). Although the duration of immunity 
induced by vaccination is formally unknown, we assumed lifelong vaccine-induced 
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protection in the base-case similar with other studies (37–39). We also assumed that 
vaccination would be performed only at the start of followed cohort (i.e., at 12 years of age), 
with vaccination decreasing the transition probabilities from susceptible to cervical cancer. 
Vaccine coverage was assumed to be 76.6% based on the school enrollment rates (40) and 
the coverage of other vaccinations (measles, diphtheria and tetanus for 7-12 years old girls) 
in Indonesia (41). 
 
Costs and Utilities 
In this study, all costs were converted into 2013 International Dollars (I$), using purchasing 
power parities conversion factors (42). With respect to the economic perspective, we only 
considered direct medical costs for cervical cancer treatment and all VIA screening-related 
activities, according to the national tariffs for primary and secondary healthcare services 
(28). Cervical cancer treatment costs (both initial and recurrent) were weighted by the 
cervical cancer treatment patterns for each stages of cervical cancer in Indonesia (34–36,43–
46) and applied for every newly-detected cervical cancer patient. The total costs for initial 
and recurrent treatments were I$4,140 and I$3,169, respectively. In the absence of a 
national vaccine price and availability of related relevant Indonesian information, we 
estimated all vaccine-related costs based on the Pan American Health Organization (PAHO) 
revolving fund, which consists of the price of a 3-dose vaccination (I$39.71), revolving fund 
(I$1.39), freight (I$1.19), insurance and wastage cost (I$1.99) (47). Thus, our assumption for 
the total vaccination costs would be I$44.27. 
 
We adopted utilities associated with cervical cancer patients based on the Health and 
Activity Limitation Index (HALex) (48), which allows calculating Quality-Adjusted Life Years 
(QALYs) by taking utilities and durations of health states into account. Finally, we 
systematically applied an annual discount rate of 3% for both future costs and utilities. 
 
Model Outcome 
We critically addressed the estimated epidemiologic and economic outcomes from each 
strategy. Predicted epidemiologic outcomes were the numbers of both prevented cervical 
cancer cases and deaths. Furthermore, as an economic outcome, we estimated the 
Incremental Cost Effectiveness Ratio (ICER) from the incremental costs divided by the 
incremental QALYs from preventive strategies, compared to no intervention. All outcomes 
were expressed for a cohort of 100,000 women through their lifetime in Indonesia.  
 
Scenario and Sensitivity Analysis 
We investigated the robustness of the ICERs by developing several scenarios with regard to 
booster dosing at 30 years of age (scenario I), if the booster dose would be required to 
obtain lifelong effectiveness of the vaccine. We also investigated the effect of cross-
protection against HPV types 31/33/45/52/58  at 25% efficacy (scenario II: low cross 
protection) (33) and 53% efficacy (scenario III: high cross protection) (13). Also, we 




IV: short protection) and 20 years (scenario V: medium protection) and waning of vaccine-
induced immunity at 95% efficacy for 10 years, followed by exponential decrease at 50% 
efficacy during each following period of 20 years (scenario VI: slow waning) or 5 years 
(scenario VII: fast waning). 
 
We based the vaccine price on PAHO revolving fund for the base-case scenario (47). In 
sensitivity analyses, we also explored potential reductions of the market price (75%, 50%, 
25% discounts on I$125.17) (49,50), both with and without booster dosing. Price reductions 
indicate potential advantages of economic upscaling and tendering effects if widespread 
vaccination would be considered to be implemented. 
 
Univariate sensitivity analyses were performed by estimating the ICERs based on changes of 
maximum and minimum values for each parameter and assumption, in order to investigate 
the most influential parameters or assumptions in the model. Parameters included in the 
univariate sensitivity analyses were vaccine efficacy, vaccine coverage, the efficacy of VIA 
screening for cervical cancer incidence and mortality, screening coverage, utilities for 
cervical cancer patients, cryotheraphy coverage and its costs.  
 
Probabilistic sensitivity analysis (PSA) was taken into account by drawing one value for each 
parameter from its respective distributions simultaneously and estimate the ICER for each 
strategy correspondingly. We repeated this process up to 1,000 times to provide a range for 
the ICER. We developed a cost-effectiveness acceptability curve (CEAC) to describe the 
relationship between potential Indonesian cost-effectiveness thresholds and the ICER, using 
the net monetary benefit approach. Based on the WHO’s criterion (24), a new intervention 
in Indonesia would be deemed very cost-effective and cost-effective if the ICER would be <1x 





The projected annual reduction in cervical cancer cases and deaths as a consequence of VIA 
screening or in combination with HPV vaccination are presented in Figure 2. Since the 
cervical cancer progression increases strongly after the age of 40, the effect of cervical 
screening is most evident in those particular ages. All susceptible women in the VIA 
screening group have an equal risk again on cervical cancer to unscreened women when the 
screening program stops after the age of 60. Oppositely, women in the vaccination group 
remain protected by the effect of HPV vaccination until the end of the model analysis. 
Assuming an 3 yearly screening coverage of 63,6% (29), screening would reduce the total 
incidence of cervical cancer from 1,842 cases to 1,697 cases (7.9% reduction), compared to 
no intervention. In addition to the screening, the effectiveness of HPV vaccination in 
reducing the incidence of cervical cancer is high, as shown in the figure 2A. Specifically, it 
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reduces the incidence of cervical cancer up to 58.5% and 55,0%, compared to no 




Figure 2. Estimated annual cases of cervical cancer prevented (A) and life years saved (B) by 
VIA screening, or VIA screening in combination with HPV vaccination. 
 
The effectiveness of VIA screening and HPV vaccination on mortality cases would increase 
gradually after 30 years and attain a peak at 65 years after introduction. Figure 2B shows 




































































substantial mortality. Specifically, these strategies reduce cervical cancer-related death 
during a lifetime with 24,58 and 97.49 cases per 100.000 women for screening alone and 
screening plus vaccination, respectively.  
 
Costs, QALYs and ICERs  
Discounted costs and QALYs from each strategy are presented in Table 2. Discounted costs 
and QALYs from VIA screening combined with HPV vaccination (I$5,588,654 and 2,724,504) 
are higher than discounted costs and QALYs from VIA screening alone (I$3,393,833 and 
2,723,129), both compared to no intervention. We also estimated that the ICER of VIA 
screening combined with HPV vaccination (I$1,863) would be slightly lower than the ICER of 
VIA screening alone (I$3,126). Apparently, based on PAHO revolving fund policy, both ICERs 
were still lower than the GDP per capita of Indonesia in 2013 (I$3,475). 
 
Table 2. Discounted costs and QALYs and cost-effectiveness in the base case for VIA 
screening and vaccination in a cohort of 100,000 women followed from 12 to 100 years of 
age 
Base case Cost QALYs 
Incremental 
Cost QALYs ICER 
No intervention 2,486,717 2,722,839 Reference Reference Reference 
VIA screening 3,393,034 2,723,129 906,317 290 3,126 




The impact of all scenarios in costs and QALYs are presented in Table 3. An addition of a 
booster dose to achieve lifelong protection has a limited effect on the ICER (I$3,040). 
Additionally, vaccine-induced cross-protection against type 31/33/45/52/58 would increase 
the ICER up to I$1,716 and I$1,570 for low (scenario II) and high cross-protection (scenario 
III), respectively. Duration of vaccine-induced protection and waning immunity gives a 
significant effect on the ICER. Specifically, a short duration of vaccine-induced protection 
(scenario IV) affected the ICER strongly, raising it up to 5 times higher than the ICER in the 
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Table 3. Discounted costs and QALYs and cost-effectiveness of various scenarios in a cohort 
of 100,000 women followed from 12 to 100 years of age for vaccination in combination with 
VIA screening vs. natural progression of cervical cancer 
 
Scenario Cost QALYs 
Incremental 
Cost QALYs ICER 
Scenario I: booster dose  7,548,979 2,724,504 5,062,262 1,665 3,040 
Scenario II: low cross-
protection 
5,506,716 2,724,599 3,019,999 1,760 1,716 
Scenario III: high cross-
protection  
5,414,894 2,724,704 2,928,178 1,865 1,570 
Scenario IV: short 
vaccine-induced 
protection (10 years) 
6,679,563 2,723,316 4,192,846 477 8,795 
Scenario V: medium 
vaccine-induced 
protection (20 years) 
6,603,330 2,723,449 4,116,613 610 6,754 
Scenario VI: slow waning 
of immunity (after 10 
years, efficacy decrease 
50% every 20 years) 
6,391,817 2,723,674 3,905,100 835 4,678 
Scenario VII: fast waning 
of immunity (after 10 
years, efficacy decrease 
50% every 5 years) 
6,630,473 2,723,395 4,143,756 556 7,458 
 
 
We also investigated the influence of the vaccine price (compared to the assumed market 
price) for both with- and without booster dose scenarios (Figure 3). The implementation of 
HPV vaccination on top of VIA screening in Indonesia would not be cost-effective under the 
normal market price of HPV vaccine (I$125.17) since the ICER would far above the 
Indonesian cost-effectiveness threshold of I$10,425 per QALY gained  (notably, I$17,106 per 
QALY without a booster dose, and I$27,092 per QALY with a booster dose). If a booster dose 
is not required to obtain lifelong protection, a 50% reduction from the market vaccine price 
(I$62.59) would achieve the ICER (I$8,466) being below the threshold. With the booster dose 







Figure 3. the effect of market vaccine price on incremental cost-effectiveness ratio in term of 




Figure 4. Cost-effectiveness acceptability curve (CEAC), specifically 1-3x GDP/capita is 
indicated with the corresponding probability to be cost-effective 
 
We performed a PSA by running a Monte Carlo simulations to test the robustness of the 
model regarding the uncertainty surrounding the input parameters. A cost-effectiveness 
acceptability curve (CEAC) is presented in Figure 4. Applying a threshold of 1xGDP (I$3,475), 
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VIA screening combined with HPV vaccination, respectively. In addition, the full range of 
simulations fell below I$7,200/QALYs and I$3,150/QALYs for VIA screening alone and VIA 




Figure 5. Univariate sensitivity analyses for VIA screening alone (A) and VIA screening 
combined with vaccination (B) compared to no intervention. 
 
We tested the influence of each parameter’s changes on the cost-effectiveness ratio in a 
univariate sensitivity analysis. A minor change in a very sensitive parameter that alters the 
ICER strongly would be find in the top in the tornado diagram. We see that the most 
sensitive parameters in the VIA screening strategy are the utilities, the discount rate, and 
cervical cancer treatment costs. In addition, the ICER was mildly sensitive to cryotherapy 






5A). The most sensitive parameters in the HPV vaccination in addition to VIA screening 
strategy were discount rates, utilities and cervical cancer treatment cost (Figure 5B). 
Discussion  
We developed a population-based Markov model to determine the cost-utility of cervical 
cancer prevention programs in Indonesia, including VIA screening with or without HPV 
vaccination. Our study revealed that either screening alone or screening in combination with 
HPV vaccination can relevantly decrease the incidence of cervical cancer and improve quality 
of life and survival. Since most of developing countries, including Indonesia, have no explicit 
cost-effectiveness criteria to justify the implementation of a new intervention, we applied 
the WHO’s recommendation on cost-effectiveness thresholds, stating that an intervention 
can be categorized as a cost-effective intervention if the ICER lies below three times the GDP 
per capita (24). As the GDP per capita of Indonesia in 2013 was approximately I$3,475 (51), 
both VIA screening (I$3,126) and VIA screening in combination with HPV vaccination 
(I$1,863) compared to doing nothing can be considered as very cost-effective strategies. 
Specifically, the most cost-effective strategy is the combination of VIA screening and HPV 
vaccination. To our knowledge, this is the first cost-utility analysis of cervical cancer 
prevention strategies in Indonesia. However, the result of this study, that HPV vaccination on 
top of cervical screening could be a cost-effective intervention, is in line with previous 
studies in other developing countries (52–57). 
 
We selected the payer’s perspective for our study, which is in line with the new policy that 
has been implemented by the Indonesian government in early 2014 to cover almost all 
health-care services in primary and secondary settings (28,58). This method provides a clear 
picture of the average cost of cervical cancer treatment in Indonesia. Although, the cost of 
cervical cancer treatment in this study is estimated either lower (59) or higher (52,60) 
compared to other countries, the addition of HPV vaccination on top of VIA screening is 
considered as a cost-effective strategy as in those other countries. 
 
As the long-term efficacy of the current HPV vaccination has not been established, we 
investigated the possibility that a booster dose would be needed to achieve lifelong 
protection. As expected, the addition of a booster dose yielded a higher ICER, but the value 
itself remained below the GDP per capita of Indonesia. This finding is also in accordance with 
other studies in several settings (37,56,61). Moreover, the vaccine’s effectiveness is not only 
influenced by the implementation of a booster dose, but also by other variables such as 
vaccination coverage, the distribution of HPV types and adherence (29,56). 
 
In this study, the effect of cross-protection against HPV types 31/33/45/52/58 is limited, as 
illustrated by limited reductions from I$1,630 in the base-case to I$1,488 and I$1,346 for 
scenarios with low-and high effect of cross-protection, respectively. This finding is similar to 
several studies from other countries, that investigated the effect of cross-protection on cost-
effectiveness (38,62). Despite the fact that the distributions of HPV types in various 
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countries are evidently different (34–36) and that this considerably influences the overall 
vaccine effectiveness from a clinical perspective, cross-protection against other hrHPV types 
can be highly interesting in other settings in South-East Asia. 
 
Based on a vaccine price derived from the PAHO revolving fund policy, the addition of 
vaccination yielded a cost-effective strategy in preventing cervical cancer. Yet, at the current 
market price of HPV vaccines it appears that the addition of HPV vaccination to VIA 
screening is not a cost-effective intervention in Indonesia. A range of 50-75% reductions 
from the vaccine market price is required to maintain HPV vaccination in combination with 
VIA screening as a cost-effective strategy. This result suggests that a reduction of HPV 
vaccine price, compared to market price will be essential for the HPV vaccine to be included 
in the immunization schedule in Indonesia. 
 
Notwithstanding the fact that a lack exists for data related to CIN or pre-cancer in Indonesia, 
our model can be considered to still validly and adequately estimate the natural history of 
cervical cancer patients in Indonesia based on actual epidemiological data from the WHO. 
For example, the natural history of cervical cancer patients, cervical cancer incidence and 
mortality rates for the population at risk could be described and implemented in the model. 
Notably, fewer assumptions were required in our model compared to a more complex 
Markov structure or even dynamic model, as we did not incorporate any transition to HPV 
infection or staging on pre-cancer and cancer stages. More complex modelling can be 
embarked upon if mare data become available. 
 
Despite the novelty of this study, it still has several limitations. Firstly, we did not take the 
vaccine protection for low risk HPV (type 6 and 11) into account. Although the data related 
to the effectiveness of both vaccines against other types of HPV is already available (63), the 
information related to the costs and QALYs caused by low-risk HPV (lrHPV) in Indonesia is 
scarce. Secondly, incorporation of genital warts as a consequence of HPV types 6 and 11 also 
will introduce further differences in clinical benefits (i.e. QALYs) between both available 
vaccines in the market. However to which extend this will be the case should be further 
investigated (64). Therefore, further research should be directed to the clinical burden and 
costs of genital warts in Indonesia to make a more precise comparison between both 
vaccines. Another limitation in this study is the potential benefit of HPV vaccines against 
non-cervical HPV-related cancers. Anal, vaginal, vulvar, and oropharingeal, recurrent 
respiratory papilomatosis and other pre-cancerous lesion were not taken into account in the 
current model. The inclusion of these types of HPV-induced diseases will increase the savings 
and quality of life gains of HPV vaccination and consequently improve the cost-effectiveness 
of HPV vaccination (65–69).  
 
Although we assumed 3-yearly screening in this model, the efficacy of the screening on 
preventing cervical cancer incidence and mortality are still considerably low. This can 




repeated screening in the model (29). Moreover, women who have negative results on their 
previous screening noticeably has lower risk of cervical cancer incidence and mortality 
compared to unscreened women. In this model we assumed that they have equal risk since 
the straightforward static Markov model has no ability to remember where the patient has 
come from nor the exact timing of that transition (70). Yet, univariate sensitivity analysis 
showed that the influence of screening efficacy on the ICER is very low. 
 
Notably, our results are consistent with previous studies from neighboring countries (20–
22,38,53,56,57) by confirming that HPV vaccination in addition to screening can be a cost-
effective intervention if it can be obtained at a price similar to, for example, the PAHO price. 
This finding may encourage the policy makers in Indonesia to further consider, decide and 
implement optimal cervical cancer prevention strategies.  
 
Conclusion 
The addition of HPV vaccination on top of VIA screening in Indonesia, even in the context of 
various conservative assumptions (need a booster dose to obtain full protection, low cross 
protection, short vaccine protection and fast waning immunity), is a very cost-effective 
strategy. Substantial clinical and economic benefits can be obtained by implementing an HPV 
vaccination program. Nevertheless, improvement of the screening program itself also 
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